Skip to Main Content


For patients with frequent exacerbations, the use of biologic agents, such as anti-IgE (omalizumab), anti-IL-5 (mepolizumab, benralizumab), or anti-IL4 receptor (dupilumab), has been shown to improve outcomes.

Koutsokera A et al. J Cyst Fibros. [PMID: 31405730]


The USPSTF updated its recommendation for low-dose CT screening. Annual low-dose CT screening for lung cancer is recommended for those at high risk; with high-risk criteria including age 50–80 years, at least a 20 pack-years smoking history, and either current smoking or quit date within past 15 years. Screening should be stopped once 15 years have elapsed since quitting smoking, or if a comorbid condition renders the benefits of screening null. Simulation models developed for the purposes of informing this recommendation found yearly screening with this parameters to be the most efficient in reducing lung-cancer related deaths, although more false-positive test results are expected compared with the original recommendation.

Krist AH et al. JAMA. [PMID: 33687470]


The aggressiveness of bronchial carcinoid tumors is determined by the cell histology, with “typical carcinoid,” a low-grade tumor, demonstrating a more indolent and favorable course than “atypical carcinoid,” an intermediate-grade tumor. Bronchial carcinoid tumor staging follows the same TNM classification as other lung cancers.

Singh S et al. J Thorac Oncol. [PMID: 32663527]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.